{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:55:44Z","timestamp":1791633344661,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007543","name":"ANSM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.therap.2024.10.059","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T12:32:13Z","timestamp":1729686733000},"page":"197-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["DRAMES and DTA databases: Complementary tools to monitor drug-related deaths in France"],"prefix":"10.1016","volume":"80","author":[{"given":"Bruno","family":"Revol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9o","family":"Willeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Manceau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Dumestre-Toulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Gaulier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lian","family":"Bertin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Eysseric-Gu\u00e9rin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Fouilh\u00e9 Sam-La\u00ef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2024.10.059_bib0200","series-title":"World Drug Report 2023 (United Nations publication)","year":"2023"},{"key":"10.1016\/j.therap.2024.10.059_bib0205","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/add.16081","article-title":"The opioid epidemic: a worldwide exploratory study using the WHO pharmacovigilance database","volume":"118","author":"Robert","year":"2023","journal-title":"Addiction"},{"key":"10.1016\/j.therap.2024.10.059_bib0210","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/ejp.1786","article-title":"Is Europe also facing an opioid crisis? A survey of European Pain Federation chapters","volume":"25","author":"H\u00e4user","year":"2021","journal-title":"Eur J Pain"},{"key":"10.1016\/j.therap.2024.10.059_bib0215","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1192\/j.eurpsy.2021.2219","article-title":"Is Europe facing an opioid crisis like the United States? An analysis of opioid use and related adverse effects in 19 European countries between 2010 and 2018","volume":"64","author":"Pierce","year":"2021","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.therap.2024.10.059_bib0220","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13054-020-02915-5","article-title":"Revisited: therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics","volume":"24","author":"Schulz","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.therap.2024.10.059_bib0225","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.therap.2024.10.059_bib0230","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.forsciint.2004.02.017","article-title":"Fatal blood and tissue concentrations of more than 200 drugs","volume":"142","author":"Musshoff","year":"2004","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.therap.2024.10.059_bib0235","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.therap.2023.06.004","article-title":"Augmentation des surdoses et d\u00e9c\u00e8s en lien avec la consommation de m\u00e9thadone durant la crise sanitaire li\u00e9e au COVID-19\u00a0en 2020","volume":"79","author":"Frauger","year":"2024","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.059_bib0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.puhe.2023.07.004","article-title":"Increase in hospitalisation-associated methadone intoxication in France following first COVID-19 lockdown","volume":"223","author":"Perino","year":"2023","journal-title":"Public Health"},{"key":"10.1016\/j.therap.2024.10.059_bib0245","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.285.1.39","article-title":"Deaths attributable to methadone vs. buprenorphine in France","volume":"285","author":"Auriacombe","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2024.10.059_bib0250","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.therap.2020.09.007","article-title":"Novel forms of injectable buprenorphine and French model of opioid use disorder treatment","volume":"75","author":"Lapeyre-Mestre","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.059_bib0255","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.puhe.2024.08.019","article-title":"Trends in fatal poisoning among medical users of analgesics in France from 2013 to 2022: an analysis of the DTA register","volume":"236","author":"Revol","year":"2024","journal-title":"Public Health"},{"key":"10.1016\/j.therap.2024.10.059_bib0260","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.therap.2019.11.002","article-title":"French trends in the misuse of fentanyl: from 2010 to 2015","volume":"75","author":"Tournebize","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.059_bib0265","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.therap.2024.02.002","article-title":"Transmucosal fentanyl-related opioid use disorder in a cancer survivor","volume":"79","author":"Mezaache","year":"2024","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.059_bib0270","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40264-021-01124-5","article-title":"A 13-year national monitoring study to assess narcotic prescriptions and indications (2007\u20132019)","volume":"45","author":"Perri-Pland\u00e9","year":"2022","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2024.10.059_bib0275","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/j.pain.0000000000002093","article-title":"Evolution of doctor shopping for oxycodone in the 67 million inhabitants in France as a proxy for potential misuse or abuse","volume":"162","author":"Soeiro","year":"2021","journal-title":"Pain"},{"key":"10.1016\/j.therap.2024.10.059_bib0280","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/fcp.12356","article-title":"Medical prescriptions falsified by the patients: a 12-year national monitoring to assess prescription drug diversion","volume":"32","author":"Jouanjus","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.059_bib0285","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/fcp.12210","article-title":"Evidence of slow-release morphine sulfate abuse and diversion: epidemiological approaches in a French administrative area","volume":"30","author":"Peyriere","year":"2016","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.059_bib0290","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1111\/bcp.14082","article-title":"Risk assessment of using off-label morphine sulfate in a population-based retrospective cohort of opioid-dependent patients","volume":"86","author":"Bertin","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.059_bib0295","doi-asserted-by":"crossref","first-page":"e76499","DOI":"10.1371\/journal.pone.0076499","article-title":"Misuse and dependence on non-prescription codeine analgesics or sedative H1 antihistamines by adults: a cross-sectional investigation in France","volume":"8","author":"Roussin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.therap.2024.10.059_bib0300","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/pds.4624","article-title":"Detecting the diverted use of psychoactive drugs by adolescents and young adults: a pilot study","volume":"27","author":"Jouanjus","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2024.10.059_bib0305","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1111\/bcp.15052","article-title":"Medical prescription forms of opioid cough suppressants falsified by the patients before and after they switched from over-the-counter to prescription-only in France","volume":"88","author":"Jouanjus","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.059_bib0310","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1111\/bcp.15323","article-title":"Increase of high-risk tramadol use and harmful consequences in France from 2013 to 2018: evidence from the triangulation of addictovigilance data","volume":"88","author":"Roussin","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.059_bib0315","doi-asserted-by":"crossref","first-page":"e2331398","DOI":"10.1001\/jamanetworkopen.2023.31398","article-title":"Trends in fatal poisoning among drug users in France from 2011 to 2021: an analysis of the DRAMES Register","volume":"6","author":"Revol","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.therap.2024.10.059_bib0320","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/fcp.12603","article-title":"Health consequences of cocaine use in France: data from the French Addictovigilance Network","volume":"35","author":"Eiden","year":"2021","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.059_bib0325","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/fcp.12815","article-title":"Ten-year trends in hospitalizations related to cocaine abuse in France","volume":"36","author":"Eiden","year":"2022","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.059_bib0330","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.therap.2022.10.003","article-title":"Increase of cannabis and cocaine use by pregnant women in France from 2005 to 2018: insights of the annual cross sectional OPPIDUM survey","volume":"78","author":"Blayac","year":"2023","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.059_bib0335","series-title":"World Drug Report 2022 (United Nations publication)","year":"2022"},{"key":"10.1016\/j.therap.2024.10.059_bib0340","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/bcp.13892","article-title":"Patterns of gabapentin and pregabalin use and misuse: results of a population-based cohort study in France","volume":"85","author":"Driot","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.059_bib0345","doi-asserted-by":"crossref","first-page":"639780","DOI":"10.3389\/fpsyt.2021.639780","article-title":"Gabapentinoid abuse in France: evidence on health consequences and new points of vigilance","volume":"12","author":"Tambon","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.therap.2024.10.059_bib0350","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1111\/bcp.15430","article-title":"Association between NMDAR antagonists, drug abuse and dependence: a disproportionality analysis from the WHO pharmacovigilance database","volume":"88","author":"Revol","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.059_bib0355","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/fcp.12995","article-title":"Patterns of ketamine use among people with substance use disorder in France: multisource analysis of the data from the French Addictovigilance Network","volume":"38","author":"Gandolfo","year":"2024","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.059_bib0360","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.therap.2021.01.058","article-title":"Thirty years of nefopam abuse in France","volume":"76","author":"Revol","year":"2021","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.059_bib0365","doi-asserted-by":"crossref","first-page":"110343","DOI":"10.1016\/j.forsciint.2020.110343","article-title":"Fatal poisoning in drug addicts in the Nordic countries in 2017","volume":"313","author":"Simonsen","year":"2020","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.therap.2024.10.059_bib0370","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1111\/add.15493","article-title":"Trends in MDMA-related mortality across four countries","volume":"116","author":"Roxburgh","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.therap.2024.10.059_bib0375","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/pds.4320","article-title":"A 15-year overview of increasing tramadol utilisation and associated mortality and the impact of tramadol classification in the United Kingdom","volume":"27","author":"Chen","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2024.10.059_bib0380","doi-asserted-by":"crossref","first-page":"108345","DOI":"10.1016\/j.drugalcdep.2020.108345","article-title":"Concomitant drugs with buprenorphine user deaths","volume":"218","author":"Mariottini","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2024.10.059_bib0385","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1111\/bcp.15352","article-title":"Fatalities associated with gabapentinoids in England (2004\u20132020)","volume":"88","author":"Kalk","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.059_bib0390","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00414-016-1358-8","article-title":"Fatal toxicity index of medicinal drugs based on a comprehensive toxicology database","volume":"130","author":"Ojanper\u00e4","year":"2016","journal-title":"Int J Legal Med"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724001756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724001756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T01:47:02Z","timestamp":1762220822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595724001756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0040595724001756"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2024.10.059","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DRAMES and DTA databases: Complementary tools to monitor drug-related deaths in France","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2024.10.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}